Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech News Iraq.
Press releases published on August 12, 2025
Acceleware Ltd. Announces Extension of Private Placement Financing
CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of cutting-edge radio frequency (“RF”) power-to-heat technologies targeting process heat for critical minerals, amine …
Satellogic Reports Second Quarter Financial Results
27% Increase in Revenue to $4.4 million Coupled with 41% Decrease in Operating Costs and Expenses in 2Q 2025 Poised to Deliver NextGen Satellite and Technology Transfer to Malaysia’s Earth Observation Satellite Program Awarded $30 Million Contract for AI- …
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026 Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of …
PubMatic to Participate in Upcoming Financial Conferences
NO-HEADQUARTERS/REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are …
Rigetti Computing Reports Second Quarter 2025 Financial Results; Announces General Availability of its 36-Qubit Multi-Chip Quantum Computer
BERKELEY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the second quarter ended June 30, 2025. …
ARRAY Technologies, Inc. to Participate in Upcoming Investor Conferences and Events
ALBUQUERQUE, N.M., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software and services, today announced its attendance at the following …
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and …
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support operations through …
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell …
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to begin enrolling …
Varonis to Present at Upcoming Investor Conference
MIAMI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced its participation at the following upcoming conference: Citi's 2025 Global TMT Conference, September 2 – 5, in New York. The presentation …
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – - Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute …
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and …
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top- …
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Precision Medicine Summit in …
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end …
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with APOL1-Mediated Kidney Disease; …
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. …
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable …
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif …